6533b85dfe1ef96bd12bdfaf
RESEARCH PRODUCT
Alpha lipoic acid efficacy in burning mouth syndrome: a controlled clinical trial
Begoña Palacios-sánchezRocío Cerero-lapiedraLuis-alberto Moreno-lópezSilvia Llamas-martínezGermán Esparza-gómezsubject
AdultMalemedicine.medical_specialtyPathologyOdontologíaBurning Mouth SyndromeDiseasePlaceboPlacebo groupGastroenterologyAntioxidantslaw.inventionDouble-Blind MethodRandomized controlled triallawInternal medicineStatistical significancemedicineHumansGeneral DentistryAgedBurning SensationAged 80 and overOral Medicine and PathologyThioctic Acidbusiness.industryResearchMiddle AgedBurning mouth syndrome:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludClinical trialTreatment OutcomeOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASFemaleSurgerymedicine.symptombusinessdescription
Background A double-blind placebo-controlled trial was conducted in order to evaluate the efficacy of alpha lipoic acid (ALA) and determine the statistical significance of the outcome variables. Burning mouth syndrome (BMS) is defined as an oral burning sensation in the absence of clinical signs which could justify the syndrome. Recent studies suggest the existence of neurological factors as a possible cause of the disease. Material and Methods 60 patients with BMS, in two groups: case group with 600 mg/day and placebo as control group; with follow up of 2 months. Results 64% of ALA patients reported some level of improvement, with a level of maintenance of 68.75% one month after treatment. 27.6% of the placebo group also demonstrated some reduction in BMS symptoms. Conclusions Long-term evolution and the intensity of symptoms are variables that reduce the probability of improvement with ALA treatment. Key words: Burning mouth syndrome, neuropathy, alpha lipoic acid.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2014-10-06 |